Trials / Completed
CompletedNCT01086449
Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in healthy ethnic Japanese adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster Vaccine GSK 1437173A | Investigational vaccine (GSK 1437173A) administered intramuscularly. |
Timeline
- Start date
- 2010-03-04
- Primary completion
- 2010-06-25
- Completion
- 2010-11-25
- First posted
- 2010-03-15
- Last updated
- 2018-03-09
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01086449. Inclusion in this directory is not an endorsement.